Eastern Cooperative Oncology Group
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Eastern Cooperative Oncology Group sits in the top decile of US sponsors by registered trial count (#198 of 15,742 sponsors by registered trial count).
Eastern Cooperative Oncology Group: 141 sponsored US clinical trials, 4 recruiting.
Eastern Cooperative Oncology Group sponsors 141 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 121 completed. 37 of these trials are in Phase 3-4 (later-stage) and 90 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Bladder Cancer, with 3 trials.
Top-decile sponsor footprint
Eastern Cooperative Oncology Group ranks in the top decile of sponsors by registered trial count (#198 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
121 of 131 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
141 total, page 1 of 3
The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials
NCT06756607
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
NCT06724237
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
NCT05289687
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
NCT05108298
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
NCT07085728
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
NCT01415752
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
NCT00978458
A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients
NCT07068074
Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Patients With a Prior History of Melanoma
NCT07040280
A Targeted Electronic Health Approach to Reduce Fear of Recurrence in Breast Cancer Survivors (FoRtitude)
NCT07122492
COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation
NCT05076266
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
NCT01242800
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy
NCT01079780
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
NCT01084083
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
NCT00700882
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
NCT00427349
Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
NCT00551759
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
NCT00335140
Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes
NCT00045305
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT00274924
Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms
NCT00217425
Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer
NCT00077129
Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary
NCT00357630
Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance
NCT00309933
Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer
NCT00303914
Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
NCT00101283
Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma
NCT00070291
Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma
NCT00057954
Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer
NCT00103207
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
NCT00098787
High-Dose Methotrexate and Leucovorin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00082797
Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
NCT00071981
Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
NCT00074282
Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer
NCT00090974
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia
NCT00060346
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
NCT00060398
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial
NCT00897767
Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium
NCT00053209
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00057837
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
NCT00064350
Esophagectomy in Treating Patients With High-Grade Dysplasia of the Esophagus or Stage I, Stage II, or Stage III Esophageal Cancer
NCT00063986
Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
NCT00062010
Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma
NCT00068393
Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
NCT00075946
Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
NCT00052884
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
NCT00049530
Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer
NCT00054561
Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
NCT00049348
Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer
NCT00027859
Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer
NCT00057876
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 87 |
| Phase 3 | 37 |
Therapeutic Areas
What is open in the Eastern Cooperative Oncology Group pipeline
4 recruiting of 141 indexed (3% open); 121 completed (86%).
Phase mix: 37 late (III/IV) vs 90 early (I/II) (early-phase heavy).
Top condition: Bladder Cancer (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Eastern Cooperative Oncology Group: open-pipeline peers nationwide
Peers matched on 141 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
Eastern Cooperative Oncology Group sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 141 trials (± recruiting share)
- Case Western Reserve University · 141 trials · 16% recruiting
- Purdue University · 141 trials · 10% recruiting
- Johnson & Johnson Vision Care · 142 trials · 1% recruiting
- Mclean Hospital · 140 trials · 19% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Merz North America · 3% recruiting · 35 trials
- VIVUS · 3% recruiting · 35 trials
- Enanta Pharmaceuticals · 3% recruiting · 36 trials
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · 3% recruiting · 138 trials
Related
What to do with this Eastern Cooperative Oncology Group page
141 registered trials is a research-attention snapshot, not an endorsement of Eastern Cooperative Oncology Group or any single study.
- 4 of Eastern Cooperative Oncology Group's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Bladder Cancer is the condition Eastern Cooperative Oncology Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Bladder Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Eastern Cooperative Oncology Group pipeline card: 141 registered trials from official public datasets.Report a data error.